Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Bristol Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
October 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
September 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
September 15, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
September 12, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Dividend
September 10, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
September 09, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
September 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
September 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
August 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
August 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
August 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
August 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
July 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
July 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
July 08, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
June 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
June 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Dividend
June 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
June 13, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
June 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
May 30, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
May 29, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.